{"id":"https://openalex.org/W2575667551","doi":"https://doi.org/10.1038/bjc.2016.419","title":"Phase II randomised discontinuation trial of the MET/VEGF receptor inhibitor cabozantinib in metastatic melanoma","display_name":"Phase II randomised discontinuation trial of the MET/VEGF receptor inhibitor cabozantinib in metastatic melanoma","publication_year":2017,"publication_date":"2017-01-19","ids":{"openalex":"https://openalex.org/W2575667551","doi":"https://doi.org/10.1038/bjc.2016.419","mag":"2575667551","pmid":"https://pubmed.ncbi.nlm.nih.gov/28103611","pmcid":"https://www.ncbi.nlm.nih.gov/pmc/articles/5318966"},"language":"en","primary_location":{"id":"doi:10.1038/bjc.2016.419","doi":"https://doi.org/10.1038/bjc.2016.419","is_oa":true,"landing_page_url":"https://doi.org/10.1038/bjc.2016.419","pdf_url":"https://www.nature.com/articles/bjc2016419.pdf","source":{"id":"https://openalex.org/S62966998","display_name":"British Journal of Cancer","issn_l":"0007-0920","issn":["0007-0920","1532-1827"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-b","doyens","jufo-2","ki-jl-2","medline","norway-2","poland-140","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310319965","host_organization_name":"Springer Nature","host_organization_lineage":["https://openalex.org/P4310319965"],"host_organization_lineage_names":["Springer Nature"],"type":"journal"},"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"British Journal of Cancer","raw_type":"journal-article"},"volume":null,"type":"article","indexed_in":["crossref","pubmed"],"open_access":{"is_oa":true,"oa_status":"hybrid","oa_url":"https://www.nature.com/articles/bjc2016419.pdf","any_repository_has_fulltext":true},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5018322482","display_name":"ADIL I. DAUD","orcid":"https://orcid.org/0000-0002-6617-8421","observed_orcids":["https://orcid.org/0000-0002-6617-8421"]},"institutions":[{"id":"https://openalex.org/I180670191","display_name":"University of California, San Francisco","ror":"https://ror.org/043mz5j54","country_code":"US","type":"education","lineage":["https://openalex.org/I180670191"]},{"id":"https://openalex.org/I4210110664","display_name":"University of California San Francisco Medical Center","ror":"https://ror.org/01t8svj65","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I4210110664"]}],"countries":["US"],"is_corresponding":true,"raw_author_name":"Adil Daud","raw_affiliation_strings":["University of California, San Francisco Medical Center at Parnassus, 1600 Divisadero Street, MZ Bldg A, San Francisco, CA 94115, USA","University of California, San Francisco Medical Center at Parnassus, 1600 Divisadero Street, MZ Bldg A, San Francisco, 94115, CA, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"University of California, San Francisco Medical Center at Parnassus, 1600 Divisadero Street, MZ Bldg A, San Francisco, CA 94115, USA","institution_ids":["https://openalex.org/I180670191","https://openalex.org/I4210110664"]},{"raw_affiliation_string":"University of California, San Francisco Medical Center at Parnassus, 1600 Divisadero Street, MZ Bldg A, San Francisco, 94115, CA, USA","institution_ids":["https://openalex.org/I180670191","https://openalex.org/I4210110664"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5001175430","display_name":"Harriet M. Kluger","orcid":"https://orcid.org/0000-0002-4932-9873","observed_orcids":["https://orcid.org/0000-0002-4932-9873"]},"institutions":[{"id":"https://openalex.org/I2802730090","display_name":"Yale Cancer Center","ror":"https://ror.org/03j7sze86","country_code":"US","type":"facility","lineage":["https://openalex.org/I2802730090","https://openalex.org/I4210117499","https://openalex.org/I4210165192"]},{"id":"https://openalex.org/I32971472","display_name":"Yale University","ror":"https://ror.org/03v76x132","country_code":"US","type":"education","lineage":["https://openalex.org/I32971472"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Harriet M Kluger","raw_affiliation_strings":["Yale Cancer Center, Yale University School of Medicine, 333 Cedar Street, PO Box 208028, New Haven, CT 06520-8028, USA","Yale Cancer Center, Yale University School of Medicine, 333 Cedar Street, PO Box 208028, New Haven, 06520-8028, CT, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Yale Cancer Center, Yale University School of Medicine, 333 Cedar Street, PO Box 208028, New Haven, CT 06520-8028, USA","institution_ids":["https://openalex.org/I2802730090","https://openalex.org/I32971472"]},{"raw_affiliation_string":"Yale Cancer Center, Yale University School of Medicine, 333 Cedar Street, PO Box 208028, New Haven, 06520-8028, CT, USA","institution_ids":["https://openalex.org/I2802730090","https://openalex.org/I32971472"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5053481267","display_name":"Razelle Kurzrock","orcid":"https://orcid.org/0000-0003-4110-1214","observed_orcids":["https://orcid.org/0000-0003-4110-1214"]},"institutions":[{"id":"https://openalex.org/I4390039236","display_name":"Moores Cancer Center","ror":"https://ror.org/01qkmtm61","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I2800935791","https://openalex.org/I36258959","https://openalex.org/I4390039236"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Razelle Kurzrock","raw_affiliation_strings":["University of California, San Diego Moores Cancer Center, 3855 Health Sciences Drive, MC #0658, La Jolla, CA 92093-0658, USA","University of California, San Diego Moores Cancer Center, 3855 Health Sciences Drive, MC #0658, La Jolla, 92093-0658, CA, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"University of California, San Diego Moores Cancer Center, 3855 Health Sciences Drive, MC #0658, La Jolla, CA 92093-0658, USA","institution_ids":["https://openalex.org/I4390039236"]},{"raw_affiliation_string":"University of California, San Diego Moores Cancer Center, 3855 Health Sciences Drive, MC #0658, La Jolla, 92093-0658, CA, USA","institution_ids":["https://openalex.org/I4390039236"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5054043060","display_name":"Frauke Schimm\u00f6ller","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I152988861","display_name":"Exelixis (United States)","ror":"https://ror.org/01e3jga91","country_code":"US","type":"company","lineage":["https://openalex.org/I152988861"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Frauke Schimmoller","raw_affiliation_strings":["Exelixis Inc., 210 E. Grand Avenue, South San Francisco, CA 94080, USA","Exelixis Inc., 210 E. Grand Avenue, South San Francisco, 94080, CA, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Exelixis Inc., 210 E. Grand Avenue, South San Francisco, CA 94080, USA","institution_ids":["https://openalex.org/I152988861"]},{"raw_affiliation_string":"Exelixis Inc., 210 E. Grand Avenue, South San Francisco, 94080, CA, USA","institution_ids":["https://openalex.org/I152988861"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5058408204","display_name":"Aaron Weitzman","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I152988861","display_name":"Exelixis (United States)","ror":"https://ror.org/01e3jga91","country_code":"US","type":"company","lineage":["https://openalex.org/I152988861"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Aaron L Weitzman","raw_affiliation_strings":["Exelixis Inc., 210 E. Grand Avenue, South San Francisco, CA 94080, USA","Exelixis Inc., 210 E. Grand Avenue, South San Francisco, 94080, CA, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Exelixis Inc., 210 E. Grand Avenue, South San Francisco, CA 94080, USA","institution_ids":["https://openalex.org/I152988861"]},{"raw_affiliation_string":"Exelixis Inc., 210 E. Grand Avenue, South San Francisco, 94080, CA, USA","institution_ids":["https://openalex.org/I152988861"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5013992684","display_name":"Thomas A. Samuel","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210108700","display_name":"Cleveland Clinic Florida","ror":"https://ror.org/0155k7414","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1316902750","https://openalex.org/I4210108700"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Thomas A Samuel","raw_affiliation_strings":["Department of Hematology/Oncology, Cleveland Clinic Florida, 2950 Cleveland Clinic Blvd, Weston, FL 33331, USA","Department of Hematology/Oncology, Cleveland Clinic Florida, 2950 Cleveland Clinic Blvd, Weston, 33331, FL, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Hematology/Oncology, Cleveland Clinic Florida, 2950 Cleveland Clinic Blvd, Weston, FL 33331, USA","institution_ids":["https://openalex.org/I4210108700"]},{"raw_affiliation_string":"Department of Hematology/Oncology, Cleveland Clinic Florida, 2950 Cleveland Clinic Blvd, Weston, 33331, FL, USA","institution_ids":["https://openalex.org/I4210108700"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5078237755","display_name":"Ali H. Moussa","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Ali H Moussa","raw_affiliation_strings":["Cancer Care Associates, 1810 E 15th Street, Tulsa, OK 74104, USA","Cancer Care Associates, 1810 E 15th Street, Tulsa, 74104, OK, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Cancer Care Associates, 1810 E 15th Street, Tulsa, OK 74104, USA","institution_ids":[]},{"raw_affiliation_string":"Cancer Care Associates, 1810 E 15th Street, Tulsa, 74104, OK, USA","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5069690249","display_name":"Michael S. Gordon","orcid":"https://orcid.org/0000-0002-7679-9504","observed_orcids":["https://orcid.org/0000-0002-7679-9504"]},"institutions":[{"id":"https://openalex.org/I4210146652","display_name":"Pinnacle Oncology Hematology","ror":"https://ror.org/043rqx383","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I4210146652"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Michael S Gordon","raw_affiliation_strings":["Pinnacle Oncology Hematology, 9055 E. Del Camino, Suite 100, Scottsdale, AZ 85258, USA","Pinnacle Oncology Hematology, 9055 E. Del Camino, Suite 100, Scottsdale, 85258, AZ, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Pinnacle Oncology Hematology, 9055 E. Del Camino, Suite 100, Scottsdale, AZ 85258, USA","institution_ids":["https://openalex.org/I4210146652"]},{"raw_affiliation_string":"Pinnacle Oncology Hematology, 9055 E. Del Camino, Suite 100, Scottsdale, 85258, AZ, USA","institution_ids":["https://openalex.org/I4210146652"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5045419282","display_name":"Geoffrey Ira Shapiro","orcid":"https://orcid.org/0000-0002-3331-4095","observed_orcids":["https://orcid.org/0000-0002-3331-4095"]},"institutions":[{"id":"https://openalex.org/I4210117453","display_name":"Dana-Farber Cancer Institute","ror":"https://ror.org/02jzgtq86","country_code":"US","type":"facility","lineage":["https://openalex.org/I4210117453"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Geoffrey I Shapiro","raw_affiliation_strings":["Department of Medical Oncology, Dana-Farber Cancer Institute, Early Drug Development Center, 450 Brookline Avenue, Boston, MA 02215, USA","Department of Medical Oncology, Dana-Farber Cancer Institute, Early Drug Development Center, 450 Brookline Avenue, Boston, 02215, MA, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Medical Oncology, Dana-Farber Cancer Institute, Early Drug Development Center, 450 Brookline Avenue, Boston, MA 02215, USA","institution_ids":["https://openalex.org/I4210117453"]},{"raw_affiliation_string":"Department of Medical Oncology, Dana-Farber Cancer Institute, Early Drug Development Center, 450 Brookline Avenue, Boston, 02215, MA, USA","institution_ids":["https://openalex.org/I4210117453"]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":9,"corresponding_author_ids":["https://openalex.org/A5018322482"],"corresponding_institution_ids":["https://openalex.org/I180670191","https://openalex.org/I4210110664"],"apc_list":{"value":5190,"currency":"USD","value_usd":5190},"apc_paid":{"value":5190,"currency":"USD","value_usd":5190},"fwci":3.1261,"has_fulltext":true,"cited_by_count":70,"citation_normalized_percentile":{"value":0.92645974,"is_in_top_1_percent":false,"is_in_top_10_percent":true},"cited_by_percentile_year":{"min":96,"max":100},"biblio":{"volume":"116","issue":"4","first_page":"432","last_page":"440"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T11533","display_name":"Melanoma and MAPK Pathways","score":0.5195000171661377,"subfield":{"id":"https://openalex.org/subfields/1312","display_name":"Molecular Biology"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},"topics":[{"id":"https://openalex.org/T11533","display_name":"Melanoma and MAPK Pathways","score":0.5195000171661377,"subfield":{"id":"https://openalex.org/subfields/1312","display_name":"Molecular Biology"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T10392","display_name":"Cutaneous Melanoma Detection and Management","score":0.266400009393692,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10158","display_name":"Cancer Immunotherapy and Biomarkers","score":0.044599998742341995,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/cabozantinib","display_name":"cabozantinib","score":0.9990000128746033},{"id":"https://openalex.org/keywords/metastatic-melanoma","display_name":"metastatic melanoma","score":0.8799999952316284},{"id":"https://openalex.org/keywords/uveal-melanoma","display_name":"uveal melanoma","score":0.996999979019165},{"id":"https://openalex.org/keywords/vegf-receptor-inhibition","display_name":"VEGF receptor inhibition","score":0.9800000190734863},{"id":"https://openalex.org/keywords/tyrosine-kinase-inhibitors","display_name":"tyrosine kinase inhibitors","score":0.8569999933242798},{"id":"https://openalex.org/keywords/oral-anticancer-drugs","display_name":"oral anticancer drugs","score":0.49000000953674316},{"id":"https://openalex.org/keywords/progression-free-survival","display_name":"progression-free survival","score":0.8429999947547913},{"id":"https://openalex.org/keywords/objective-response-rate","display_name":"objective response rate","score":0.972000002861023},{"id":"https://openalex.org/keywords/adverse-events","display_name":"adverse events","score":0.6600000262260437},{"id":"https://openalex.org/keywords/peritonitis","display_name":"peritonitis","score":0.5450000166893005}],"concepts":[{"id":"https://openalex.org/C2781064419","wikidata":"https://www.wikidata.org/wiki/Q795057","display_name":"Cabozantinib","level":3,"score":0.9724230766296387},{"id":"https://openalex.org/C2778715236","wikidata":"https://www.wikidata.org/wiki/Q55622662","display_name":"Discontinuation","level":2,"score":0.8304446935653687},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.703357458114624},{"id":"https://openalex.org/C167734588","wikidata":"https://www.wikidata.org/wiki/Q4356503","display_name":"VEGF receptors","level":2,"score":0.5680124163627625},{"id":"https://openalex.org/C143998085","wikidata":"https://www.wikidata.org/wiki/Q162555","display_name":"Oncology","level":1,"score":0.5643941760063171},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.4883968234062195},{"id":"https://openalex.org/C2777658100","wikidata":"https://www.wikidata.org/wiki/Q180614","display_name":"Melanoma","level":2,"score":0.4767611622810364},{"id":"https://openalex.org/C2778820342","wikidata":"https://www.wikidata.org/wiki/Q906415","display_name":"Tyrosine-kinase inhibitor","level":3,"score":0.4736332297325134},{"id":"https://openalex.org/C502942594","wikidata":"https://www.wikidata.org/wiki/Q3421914","display_name":"Cancer research","level":1,"score":0.35793784260749817},{"id":"https://openalex.org/C121608353","wikidata":"https://www.wikidata.org/wiki/Q12078","display_name":"Cancer","level":2,"score":0.2575436234474182}],"mesh":[{"descriptor_ui":"D000098943","descriptor_name":"Uveal Melanoma","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000328","descriptor_name":"Adult","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000368","descriptor_name":"Aged","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000369","descriptor_name":"Aged, 80 and over","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000813","descriptor_name":"Anilides","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":true},{"descriptor_ui":"D000970","descriptor_name":"Antineoplastic Agents","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":true},{"descriptor_ui":"D001530","descriptor_name":"Belgium","qualifier_ui":"Q000453","qualifier_name":"epidemiology","is_major_topic":false},{"descriptor_ui":"D005260","descriptor_name":"Female","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D006801","descriptor_name":"Humans","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D007557","descriptor_name":"Israel","qualifier_ui":"Q000453","qualifier_name":"epidemiology","is_major_topic":false},{"descriptor_ui":"D008297","descriptor_name":"Male","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D008545","descriptor_name":"Melanoma","qualifier_ui":"Q000188","qualifier_name":"drug therapy","is_major_topic":true},{"descriptor_ui":"D008545","descriptor_name":"Melanoma","qualifier_ui":"Q000401","qualifier_name":"mortality","is_major_topic":false},{"descriptor_ui":"D008545","descriptor_name":"Melanoma","qualifier_ui":"Q000473","qualifier_name":"pathology","is_major_topic":false},{"descriptor_ui":"D008875","descriptor_name":"Middle Aged","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D009362","descriptor_name":"Neoplasm Metastasis","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D011725","descriptor_name":"Pyridines","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":true},{"descriptor_ui":"D012878","descriptor_name":"Skin Neoplasms","qualifier_ui":"Q000188","qualifier_name":"drug therapy","is_major_topic":true},{"descriptor_ui":"D012878","descriptor_name":"Skin Neoplasms","qualifier_ui":"Q000473","qualifier_name":"pathology","is_major_topic":false},{"descriptor_ui":"D014481","descriptor_name":"United States","qualifier_ui":"Q000453","qualifier_name":"epidemiology","is_major_topic":false},{"descriptor_ui":"D014604","descriptor_name":"Uveal Neoplasms","qualifier_ui":"Q000188","qualifier_name":"drug therapy","is_major_topic":true},{"descriptor_ui":"D014604","descriptor_name":"Uveal Neoplasms","qualifier_ui":"Q000401","qualifier_name":"mortality","is_major_topic":false},{"descriptor_ui":"D014604","descriptor_name":"Uveal Neoplasms","qualifier_ui":"Q000473","qualifier_name":"pathology","is_major_topic":false},{"descriptor_ui":"D016019","descriptor_name":"Survival Analysis","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D019859","descriptor_name":"Proto-Oncogene Proteins c-met","qualifier_ui":"Q000037","qualifier_name":"antagonists & inhibitors","is_major_topic":false},{"descriptor_ui":"D028761","descriptor_name":"Withholding Treatment","qualifier_ui":"Q000706","qualifier_name":"statistics & numerical data","is_major_topic":true},{"descriptor_ui":"D040262","descriptor_name":"Receptors, Vascular Endothelial Growth Factor","qualifier_ui":"Q000037","qualifier_name":"antagonists & inhibitors","is_major_topic":false}],"locations_count":6,"locations":[{"id":"doi:10.1038/bjc.2016.419","doi":"https://doi.org/10.1038/bjc.2016.419","is_oa":true,"landing_page_url":"https://doi.org/10.1038/bjc.2016.419","pdf_url":"https://www.nature.com/articles/bjc2016419.pdf","source":{"id":"https://openalex.org/S62966998","display_name":"British Journal of Cancer","issn_l":"0007-0920","issn":["0007-0920","1532-1827"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-b","doyens","jufo-2","ki-jl-2","medline","norway-2","poland-140","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310319965","host_organization_name":"Springer Nature","host_organization_lineage":["https://openalex.org/P4310319965"],"host_organization_lineage_names":["Springer Nature"],"type":"journal"},"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"British Journal of Cancer","raw_type":"journal-article"},{"id":"pmh:oai:pubmedcentral.nih.gov:5318966","doi":null,"is_oa":true,"landing_page_url":"https://www.ncbi.nlm.nih.gov/pmc/articles/5318966","pdf_url":null,"source":{"id":"https://openalex.org/S2764455111","display_name":"PubMed Central","issn_l":null,"issn":null,"is_oa":true,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Br J Cancer","raw_type":"Text"},{"id":"pmid:28103611","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/28103611","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"British journal of cancer","raw_type":"Clinical Trial, Phase II"},{"id":"pmh:oai:escholarship.org/ark:/13030/qt51x6k09n","doi":null,"is_oa":false,"landing_page_url":"https://escholarship.org/uc/item/51x6k09n","pdf_url":null,"source":{"id":"https://openalex.org/S4306400115","display_name":"eScholarship (California Digital Library)","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I2801248553","host_organization_name":"California Digital Library","host_organization_lineage":["https://openalex.org/I2801248553"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"submittedVersion","is_accepted":false,"is_published":false,"raw_source_name":"British journal of cancer, vol 116, iss 4","raw_type":"article"},{"id":"pmh:oai:escholarship.org:ark:/13030/qt51x6k09n","doi":null,"is_oa":false,"landing_page_url":"https://escholarship.org/uc/item/51x6k09n","pdf_url":null,"source":{"id":"https://openalex.org/S4306400115","display_name":"eScholarship (California Digital Library)","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I2801248553","host_organization_name":"California Digital Library","host_organization_lineage":["https://openalex.org/I2801248553"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"submittedVersion","is_accepted":false,"is_published":false,"raw_source_name":"British Journal of Cancer, vol 116, iss 4","raw_type":"article"},{"id":"pmh:qt51x6k09n","doi":null,"is_oa":false,"landing_page_url":"http://www.escholarship.org/uc/item/51x6k09n","pdf_url":null,"source":{"id":"https://openalex.org/S4306400115","display_name":"eScholarship (California Digital Library)","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I2801248553","host_organization_name":"California Digital Library","host_organization_lineage":["https://openalex.org/I2801248553"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"submittedVersion","is_accepted":false,"is_published":false,"raw_source_name":"Daud, A; Kluger, HM; Kurzrock, R; Schimmoller, F; Weitzman, AL; Samuel, TA; \u00c2\u00a0et al.(2017). Phase II randomised discontinuation trial of the MET/VEGF receptor inhibitor cabozantinib in metastatic melanoma. BRITISH JOURNAL OF CANCER, 116(4), 432 - 440. doi: 10.1038/bjc.2016.419. UC San Diego: Retrieved from: http://www.escholarship.org/uc/item/51x6k09n","raw_type":"article"}],"best_oa_location":{"id":"doi:10.1038/bjc.2016.419","doi":"https://doi.org/10.1038/bjc.2016.419","is_oa":true,"landing_page_url":"https://doi.org/10.1038/bjc.2016.419","pdf_url":"https://www.nature.com/articles/bjc2016419.pdf","source":{"id":"https://openalex.org/S62966998","display_name":"British Journal of Cancer","issn_l":"0007-0920","issn":["0007-0920","1532-1827"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-b","doyens","jufo-2","ki-jl-2","medline","norway-2","poland-140","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310319965","host_organization_name":"Springer Nature","host_organization_lineage":["https://openalex.org/P4310319965"],"host_organization_lineage_names":["Springer Nature"],"type":"journal"},"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"British Journal of Cancer","raw_type":"journal-article"},"sustainable_development_goals":[{"id":"https://metadata.un.org/sdg/3","display_name":"Good health and well-being","score":1.0}],"sustainable_development_goals_aurora":[{"id":"https://metadata.un.org/sdg/3","display_name":"Good health and well-being","score":0.8100000023841858}],"study_designs":[{"id":"https://openalex.org/study-designs/clinical-trial","display_name":"Clinical Trial"}],"awards":[],"funders":[{"id":"https://openalex.org/F4320312140","display_name":"Exelixis","ror":"https://ror.org/01e3jga91"}],"has_content":{"pdf":true,"grobid_xml":true},"content_urls":{"pdf":"https://content.openalex.org/works/W2575667551.pdf","grobid_xml":"https://content.openalex.org/works/W2575667551.grobid-xml"},"referenced_works_count":53,"referenced_works":["https://openalex.org/W1217284267","https://openalex.org/W1967600348","https://openalex.org/W1969717303","https://openalex.org/W1972539651","https://openalex.org/W1990675339","https://openalex.org/W1992112921","https://openalex.org/W1996547486","https://openalex.org/W1997919830","https://openalex.org/W2016569548","https://openalex.org/W2017304259","https://openalex.org/W2025465282","https://openalex.org/W2026652849","https://openalex.org/W2038434969","https://openalex.org/W2039013742","https://openalex.org/W2049884397","https://openalex.org/W2052005627","https://openalex.org/W2055624262","https://openalex.org/W2059132922","https://openalex.org/W2073680312","https://openalex.org/W2077517114","https://openalex.org/W2091537641","https://openalex.org/W2094337993","https://openalex.org/W2096387850","https://openalex.org/W2097995306","https://openalex.org/W2100945326","https://openalex.org/W2101918466","https://openalex.org/W2104919212","https://openalex.org/W2111863560","https://openalex.org/W2117961097","https://openalex.org/W2121545342","https://openalex.org/W2125635172","https://openalex.org/W2128035403","https://openalex.org/W2128542677","https://openalex.org/W2136146667","https://openalex.org/W2139248078","https://openalex.org/W2149026055","https://openalex.org/W2149751030","https://openalex.org/W2156604529","https://openalex.org/W2157151684","https://openalex.org/W2158011521","https://openalex.org/W2163188200","https://openalex.org/W2164699117","https://openalex.org/W2166262263","https://openalex.org/W2166662937","https://openalex.org/W2168143310","https://openalex.org/W2320786076","https://openalex.org/W2395127811","https://openalex.org/W2468601751","https://openalex.org/W2494710064","https://openalex.org/W2518470597","https://openalex.org/W2560367415","https://openalex.org/W2572174216","https://openalex.org/W2913613732"],"related_works":["https://openalex.org/W2319216644","https://openalex.org/W2528809664","https://openalex.org/W2766967055","https://openalex.org/W2976929154","https://openalex.org/W2534856746","https://openalex.org/W2469095888","https://openalex.org/W2188135389","https://openalex.org/W2739361661","https://openalex.org/W2315499684","https://openalex.org/W1989576302"],"abstract_inverted_index":{"BACKGROUND:":[0],"A":[1],"phase":[2],"II":[3],"randomised":[4,59],"discontinuation":[5],"trial":[6],"assessed":[7],"cabozantinib":[8,34,61,138],"(XL184),":[9],"an":[10],"orally":[11],"bioavailable":[12],"inhibitor":[13],"of":[14,26,99,117,124,146],"tyrosine":[15],"kinases":[16],"including":[17,206],"VEGF":[18],"receptors,":[19],"MET,":[20],"and":[21,74,88,121,139,162,181],"AXL,":[22],"in":[23,51,108,115,122,201],"a":[24,39],"cohort":[25],"patients":[27,81,100,119,126,202],"with":[28,43,127,137,142,203],"metastatic":[29,204],"melanoma.":[30,129,208],"METHODS:":[31],"Patients":[32,42],"received":[33],"100":[35],"mg":[36],"daily":[37],"during":[38],"12-week":[40],"lead-in.":[41],"stable":[44],"disease":[45],"(SD)":[46],"per":[47],"Response":[48],"Evaluation":[49],"Criteria":[50],"Solid":[52],"Tumours":[53],"(RECIST)":[54],"at":[55,71],"week":[56,72,92],"12":[57,73],"were":[58,66,82,176],"to":[60,193],"or":[62],"placebo.":[63],"Primary":[64],"endpoints":[65],"objective":[67],"response":[68],"rate":[69],"(ORR)":[70],"postrandomisation":[75],"progression-free":[76],"survival":[77,165],"(PFS).":[78],"RESULTS:":[79],"Seventy-seven":[80],"enroled":[83],"(62%":[84],"cutaneous,":[85],"30%":[86],"uveal,":[87],"8%":[89],"mucosal).":[90],"At":[91],"12,":[93],"the":[94,104],"ORR":[95],"was":[96,113,134,155,160,166,188],"5%;":[97],"39%":[98],"had":[101],"SD.":[102],"During":[103],"lead-in":[105],"phase,":[106],"reduction":[107],"target":[109],"lesions":[110],"from":[111,151,190],"baseline":[112],"seen":[114],"55%":[116],"evaluable":[118,125],"overall":[120,164],"59%":[123],"uveal":[128,207],"Median":[130,149],"PFS":[131,150,159],"after":[132],"randomisation":[133],"4.1":[135],"months":[136,141],"2.8":[140],"placebo":[143],"(hazard":[144],"ratio":[145],"0.59;":[147],"P=0.284).":[148],"study":[152],"day":[153],"1":[154],"3.8":[156],"months,":[157],"6-month":[158],"33%,":[161],"median":[163],"9.4":[167],"months.":[168],"The":[169],"most":[170],"common":[171],"grade":[172],"3/4":[173],"adverse":[174],"events":[175],"fatigue":[177],"(14%),":[178],"hypertension":[179],"(10%),":[180],"abdominal":[182],"pain":[183],"(8%).":[184],"One":[185],"treatment-related":[186],"death":[187],"reported":[189],"peritonitis":[191],"due":[192],"diverticular":[194],"perforation.":[195],"CONCLUSIONS:":[196],"Cabozantinib":[197],"has":[198],"clinical":[199,210],"activity":[200],"melanoma,":[205],"Further":[209],"investigation":[211],"is":[212],"warranted.":[213]},"counts_by_year":[{"year":2026,"cited_by_count":2},{"year":2025,"cited_by_count":3},{"year":2024,"cited_by_count":7},{"year":2023,"cited_by_count":6},{"year":2022,"cited_by_count":6},{"year":2021,"cited_by_count":18},{"year":2020,"cited_by_count":5},{"year":2019,"cited_by_count":8},{"year":2018,"cited_by_count":11},{"year":2017,"cited_by_count":4}],"updated_date":"2026-10-31T12:09:11.096373","created_date":"2017-01-26T00:00:00"}